Cargando…
Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies
Cancer is a major health burden worldwide, and despite continuous advances in medical therapies, resistance to standard drugs and adverse effects still represent an important cause of therapeutic failure. There is a growing evidence that gut bacteria can affect the response to chemo- and immunothera...
Autores principales: | Panebianco, Concetta, Andriulli, Angelo, Pazienza, Valerio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5964925/ https://www.ncbi.nlm.nih.gov/pubmed/29789015 http://dx.doi.org/10.1186/s40168-018-0483-7 |
Ejemplares similares
-
Pharmacomicrobiomics: Exploiting the Drug-Microbiota Interactions in Antihypertensive Treatment
por: Chen, Hui-Qing, et al.
Publicado: (2022) -
Pharmacomicrobiomics in Anticancer Therapies: Why the Gut Microbiota Should Be Pointed Out
por: Conti, Gabriele, et al.
Publicado: (2022) -
Microbiota Manipulation by Probiotics Administration as Emerging Tool in Cancer Prevention and Therapy
por: Panebianco, Concetta, et al.
Publicado: (2020) -
Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes
por: Ting, Nick Lung-Ngai, et al.
Publicado: (2022) -
Pharmacomicrobiomics of Classical Immunosuppressant Drugs: A Systematic Review
por: Manes, Annalaura, et al.
Publicado: (2023)